Novo's earnings results Wednesday differ from Eli Lilly's, whose stock slid on slower-than-expected sales of weight loss ...

CagriSema, considered a successor to Wegovy, is Novo Nordisk’s most likely route of gaining GLP-1RA market share back from ...

Eli Lilly and Company's impressive Q4 earnings driven by tirzepatide's success, diverse portfolio, and promising pipeline.

Novo Nordisk today announced 2024 earnings, reporting a 26% increase in annual sales to ~$40.56bn. Read why I upgrade NVO ...

Just how much Medicare price negotiations will negatively impact Novo Nordisk, though, depends on what the final negotiated prices for Ozempic, Wegovy, and Rybelsus will be. In Medicare's negotiations ...

The term "blue chip" originated from poker, where blue chips were the highest denomination of chips used in the game.

On its last weekday in power, the Biden Administration has chosen the next batch of drugs up for price negotiation in ...

Ozempic and Wegovy are now two of the biggest blockbuster ... This sell-off wiped around $19.5 billion off the big drugmaker's market cap. Just how much Medicare price negotiations will negatively ...

If the proposed rule is finalized, negotiated prices on Ozempic, Wegovy and Rybelsus would be ... On Jan. 1, a new $2,000 out-of-pocket cap on prescription drugs for Part D enrollees went into ...

President Trump has ended a Biden administration effort to lower the cost of prescription drugs for people on Medicare and Medicaid.

The blockbuster diabetes and weight-loss drug semaglutide (Ozempic, Rybelsus, Wegovy) along with therapies for asthma, cancers, and various other conditions were among the 15 drugs the Biden ...